Author

A Bowirrat

Department of Molecular Biology and Adelson School of Medicine, Ariel University, Ariel 40700 - Cited by 2,778 - Medicine and Molecular Biology

Biography

Prof. Dr. Bowirrat Abdalla M.D., Ph.D. has completed his MD from Rome University, his residency in Clinical Neurology from London University, UK, his PhD from Tel-Aviv University, Israel and postdoctoral studies from Boston University, USA. He received his Professorship from Boston University. He has published more than 120 manuscripts and 6 books in reputed journals and has been serving as an editorial board member of repute. Furthermore, he received many international awards including the Bruce S. Schoenberg international award in Neuroepidemiology of AD from the American Academy of Neurology.
Title
Cited by
Year
Understanding the scientific basis of post-traumatic stress disorder (PTSD): precision behavioral management overrides stigmatization
K Blum, MC Gondré-Lewis, EJ Modestino, L Lott, D Baron, D Siwicki, ...Molecular neurobiology 56, 7836-7850, 2019201
30
2019
27
2020
Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD)
K Blum, A Bowirrat, D Baron, L Lott, JV Ponce, R Brewer, D Siwicki, ...Journal of systems and integrative neuroscience 6 (2), 2020202
26
2020
A novel precision approach to overcome the “addiction pandemic” by incorporating genetic addiction risk severity (GARS) and dopamine homeostasis restoration
K Blum, S Kazmi, EJ Modestino, BW Downs, D Bagchi, D Baron, ...Journal of Personalized Medicine 11 (3), 212, 2021202
19
2021
Reward deficiency syndrome (RDS) surprisingly is evolutionary and found everywhere: is it “Blowin’in the wind”?
K Blum, T McLaughlin, A Bowirrat, EJ Modestino, D Baron, LL Gomez, ...Journal of Personalized Medicine 12 (2), 321, 2022202
18
2022
Exploration of epigenetic state hyperdopaminergia (Surfeit) and genetic trait hypodopaminergia (Deficit) during adolescent brain development
K Blum, A Bowirrat, MCG Lewis, TA Simpatico, M Ceccanti, B Steinberg, ...Current psychopharmacology 10, 2021202
16
2021
Death by Opioids: Are there non-addictive scientific solutions?
BW Downs, K Blum, D Baron, A Bowirrat, L Lott, R Brewer, B Boyett, ...Journal of systems and integrative neuroscience 5, 2019201
15
2019
Reward Deficiency Syndrome (RDS): a cytoarchitectural common neurobiological trait of all addictions
K Blum, A Bowirrat, ER Braverman, D Baron, JL Cadet, S Kazmi, I Elman, ...International Journal of Environmental Research and Public Health 18 (21), 129, 2021202
15
2021
The growing burden of cancer in the Gaza Strip
B Abdalla, M Mansour, M Ghanim, B Aia, M YassinThe Lancet Oncology 20 (8), 1054-1056, 2019201
14
2019
Cannabis-induced hypodopaminergic anhedonia and cognitive decline in humans: embracing putative induction of dopamine homeostasis
K Blum, J Khalsa, JL Cadet, D Baron, A Bowirrat, B Boyett, L Lott, ...Frontiers in Psychiatry 12, 623403, 2021202
13
2021
MYORG-related disease is associated with central pontine calcifications and atypical parkinsonism
V Chelban, M Carecchio, G Rea, A Bowirrat, S Kirmani, L Magistrelli, ...Neurology Genetics 6 (2), 2020202
12
2020
A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing “Precision …
K Blum, B Steinberg, MC Gondre-Lewis, D Baron, EJ Modestino, ...Psychology Research and Behavior Management, 2115-2134, 2021202
10
2021
Should we embrace the incorporation of genetically guided “dopamine homeostasis” in the treatment of reward deficiency syndrome (RSD) as a frontline therapeutic modality?
K Blum, A Raza, T Schultz, R Jalali, R Green, R Brewer, PK Thanos, ...Acta scientific neurology 4 (2), 17, 2021202
10
2021
Neurobiology and Spirituality in Addiction Recovery
AK Roy, A Bowirrat, DE Smith, ER Braverman, R Jalali, RD Badgaiyan, ...Acta scientific neurology 4 (9), 64, 2021202
10
2021
Hypothesizing in the face of the opioid crisis coupling Genetic Addiction Risk Severity (GARS) testing with electrotherapeutic nonopioid modalities such as H-Wave could …
A Gupta, A Bowirrat, LL Gomez, D Baron, I Elman, J Giordano, R Jalali, ...International Journal of Environmental Research and Public Health 1 (1), 552, 2022202
9
2022
Hypothesizing nutrigenomic-based precision anti-obesity treatment and prophylaxis: Should we be targeting sarcopenia induced brain dysfunction?
K Blum, MS Gold, L Llanos-Gomez, R Jalali, PK Thanos, A Bowirrat, ...International Journal of Environmental Research and Public Health 18 (18), 774, 2021202
9
2021
Proposing a “brain health checkup (BHC)” as a global potential “standard of care” to overcome reward dysregulation in primary care medicine: coupling genetic risk testing and …
ER Braverman, CA Dennen, MS Gold, A Bowirrat, A Gupta, D Baron, ...International Journal of Environmental Research and Public Health 1 (), 5480, 2022202
9
2022
Dopaminylation in psychostimulant use disorder protects against psychostimulant seeking behavior by normalizing nucleus accumbens (NAc) dopamine expression
K Blum, MS Gold, JL Cadet, D Baron, A Bowirrat, PK Thanos, R Brewer, ...Current psychopharmacology 11 (1), 11, 2022202
6
2022
Endorphinergic Enhancement Attenuation of Post-traumatic Stress Disorder (PTSD) via Activation of Neuro-immunological Function in the Face of a Viral Pandemic
K Blum, EJ Modestino, D Baron, R Brewer, P Thanos, I Elman, ...Current psychopharmacology 10 (2), 8-97, 2021202
6
2021
Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case–Control Subjects
Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,5 Case–Control SubjectsK Blum, D Han, A Gupta, D Baron, ER Braverman, CA Dennen, S Kazmi, ...Journal of Personalized Medicine 12 (9), 1385, 2022202
6
2022